Company intelligence / Profile preview
Tecnimede
Sintra, Lisboa, Portugaltecnimede.com ↗
- Ownership
- Private
- Employees
- ~700
- Development stage
- Commercial
01
Overview
Tecnimede has a broad commercial portfolio of over +130 products marketed in more than100 countries. The company develops both generic medicines and innovative fixed-dose combinations/new chemical entities. Its R&D activities include preclinical studies through Phase II/III clinical trials for select programs. It has a strong focus on cardiovascular/metabolic/CNS/infectious disease areas.[1][2][5][6]
- Therapeutic areas
- Metabolic Disorders
- Modalities
- Small molecules (generics and new chemical entities)[8]Fixed-dose combinations[8]Modified release formulations[8]Sterile forms[8]
- Industry
- Pharma
02
Drug pipeline
1 asset03
Partnerships
Academic collaborations with University of Coimbra and other European pharmacy faculties for research & contract development.[8]
Beyond the preview
Go deeper on Tecnimede.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tecnimede.